Holmium Laser Enucleation of the Prostate Is Safe in Patients with Prostate Cancer and Lower Urinary Tract Symptoms—A Retrospective Feasibility Study

2014 ◽  
Vol 28 (3) ◽  
pp. 335-341 ◽  
Author(s):  
Andreas Becker ◽  
Anne Placke ◽  
Luis Kluth ◽  
Rudolf Schwarz ◽  
Hendrik Isbarn ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Urinary Tract ◽  
Feasibility Study ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Holmium Laser ◽  
Urinary Tract Symptoms ◽  
Laser Enucleation ◽  
Holmium Laser Enucleation ◽  
Lower Urinary

scholarly journals Efficacy, safety, and perioperative outcomes of holmium laser enucleation of the prostate—a comparison of patients with lower urinary tract symptoms and urinary retention

2020 ◽  
Author(s):  
Pawel Trotsenko ◽  
Christian Wetterauer ◽  
Philipp Grimsehl ◽  
Tilmann Möltgen ◽  
Susan Meierhans ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Urinary Retention ◽  
Lower Urinary Tract Symptoms ◽  
Functional Outcomes ◽  
Lower Urinary Tract ◽  
Complication Rates ◽  
Urinary Tract Symptoms ◽  
Laser Enucleation ◽  
Holmium Laser Enucleation ◽  
Lower Urinary

Abstract Holmium laser enucleation of the prostate (HoLEP) is a valid treatment option to relieve bladder outlet obstruction in patients with large prostate volumes (PV). Its efficacy, tolerability, and safety are comparable to the ones of other laser treatments of the prostate and resection techniques. However, safety and efficacy of HoLEP have not been compared between patients with and without preoperative urinary retention. We included 350 patients (mean age 71.2 years) who had undergone HoLEP due to lower urinary tract symptoms (LUTS) or urinary retention caused by prostatic hyperplasia. We evaluated the differences in peri- and postoperative outcomes and complications between patients with and patients without preoperative urinary retention. The mean PV was 115 cm3. PV was > 100 cm3 in 61.9% and < 100 cm3 in 38.1% of the patients. Perioperative complications occurred in 23 patients (6.6%), 15 of which (4.3%) required operative revision. We found no significant differences in terms of complication rates between patients with PV > 100 cm3 and patients with PV < 100 cm3. Mean catheterization-duration was 3.3 days. Preoperatively, 140 patients (40%) had a suprapubic or transurethral indwelling catheter; they did not differ from patients without preoperative catheter regarding postoperative catheter removal success rate, early postoperative complications, and functional outcomes. Prostate cancer was diagnosed in 43 patients (12.3%). Median postoperative PSA-decline was 6.1 ug/l (89.8% drop). HoLEP is a safe and effective treatment for patients with LUTS or urinary retention and large PV. PV > 100 cm3 was not associated with higher complication rates or successful catheter-removal. Furthermore, functional outcomes were independent of preoperative catheterization.

Sign in / Sign up

Export Citation Format

Share Document